The passage of HB1604 is expected to have significant implications for both domestic producers and the meat market at large. By enforcing stricter labeling guidelines, the bill aims to bolster the reputation of American beef products, potentially increasing demand and providing a competitive edge in the global market. However, compliance with these stricter standards may pose challenges for some producers, especially those who source cattle from outside the U.S. or engage in mixed sourcing practices.
Summary
House Bill 1604, known as the U.S.A. Beef Act, proposes amendments to the Federal Meat Inspection Act to strictly regulate the labeling of beef products as 'Product of U.S.A.'. The bill stipulates that such labeling can only be used on meat products derived exclusively from cattle that are born, raised, and slaughtered within the United States. This move is seen as an effort to increase transparency and support domestic agriculture, ensuring that consumers can make informed decisions about the origin of their meat products.
Contention
While supporters of the bill argue that it will protect American farmers and provide consumers with clearer information, critics raise concerns about the potential economic impact on the meat industry. Some fear that the stringent labeling requirements could lead to increased costs for producers, which might ultimately translate into higher prices for consumers. There are also questions surrounding enforcement and the feasibility of monitoring compliance, especially for smaller operations that may not have the resources to adapt to the new regulations.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally, a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for an urgent medical need not involving a specific patient if, among other requirements (1) the prescriber certifies that the prescriber is unable, despite reasonable attempts, to obtain certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.
Suspends the fees collected and remitted to the Missouri Beef Industry Council until the United States Congress passes a law mandating country of origin label for beef
Suspends the fees collected and remitted to the Missouri Beef Industry Council until the United States Congress passes a law mandating country of origin label for beef
SNAP Theft Protection Act of 2023 This bill directs the Department of Agriculture (USDA) to establish criteria for state agencies to identify Supplemental Nutrition Assistance Program (SNAP) benefits stolen by identity theft or typical skimming practices and provide for the reissuance of stolen SNAP benefits to households that meet such criteria. USDA must periodically review and modify its regulations to take into account evolving technology and the threat landscape to better protect against theft.